Systematic Financial Management LP Boosts Holdings in Azenta, Inc. $AZTA

Systematic Financial Management LP boosted its holdings in shares of Azenta, Inc. (NASDAQ:AZTA) by 25.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 557,678 shares of the company’s stock after buying an additional 111,447 shares during the quarter. Systematic Financial Management LP’s holdings in Azenta were worth $11,784,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd increased its holdings in Azenta by 2,067.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock valued at $27,000 after buying an additional 765 shares during the last quarter. Assetmark Inc. boosted its stake in shares of Azenta by 54.1% during the 4th quarter. Assetmark Inc. now owns 832 shares of the company’s stock worth $28,000 after acquiring an additional 292 shares during the last quarter. Osaic Holdings Inc. boosted its stake in shares of Azenta by 44.9% during the 2nd quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after acquiring an additional 385 shares during the last quarter. Rockefeller Capital Management L.P. grew its position in shares of Azenta by 98.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock valued at $46,000 after acquiring an additional 689 shares during the period. Finally, Van ECK Associates Corp grew its position in shares of Azenta by 141.2% during the 4th quarter. Van ECK Associates Corp now owns 1,585 shares of the company’s stock valued at $53,000 after acquiring an additional 928 shares during the period. 99.08% of the stock is currently owned by institutional investors.

Azenta Trading Down 3.3%

NASDAQ AZTA opened at $27.37 on Friday. Azenta, Inc. has a 12 month low of $15.93 and a 12 month high of $41.73. The stock has a market cap of $1.26 billion, a price-to-earnings ratio of -6.91 and a beta of 1.37. The company’s 50 day moving average is $23.69 and its two-hundred day moving average is $26.12.

Azenta (NASDAQ:AZTA) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of $0.12 by ($0.16). The firm had revenue of $144.79 million for the quarter, compared to analysts’ expectations of $148.47 million. Azenta had a negative net margin of 30.49% and a positive return on equity of 1.23%. Azenta’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.01 EPS.

Analysts Set New Price Targets

A number of equities analysts recently commented on AZTA shares. Needham & Company LLC decreased their target price on Azenta from $44.00 to $33.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Weiss Ratings raised Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Azenta currently has a consensus rating of “Hold” and an average price target of $40.40.

Azenta Company Profile

Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end?to?end sample tracking workflows.

In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next?generation sequencing (NGS), DNA synthesis, and molecular biology services.